Regulatory and effector T cell subsets in tumor-draining lymph nodes of patients with squamous cell carcinoma of head and neck

[61] Tang YL(1998)Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients Proc Natl Acad Sci USA 95 707-864

[62] Liang XH(2016)Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature Cytokine Growth Factor Rev 31 744-e174

[63] Allen CT(2016)Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Cancer Res 76 859-E93

[64] Clavijo PE(2014)Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors Acta Otolaryngol 134 e167-873

[65] Van Waes C(2012)Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice Med Oncol 29 292-622

[66] Chen Z(2010)The untold story of IFN-gamma in cancer biology Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 109 E85-343

[67] Reichert TE(2014)Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer Acta Otolaryngol 134 863-472

[68] Strauss L(2009)Regulatory T-cell infiltration in tongue squamous cell carcinoma Oral Oncol 45 617-2643

[69] Wagner EM(2009)The correlation between tumor-infiltrating Foxp3 BMC Cancer 9 335-1678

[70] Gooding W(2013) regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers Int J Cancer 132 465-597

[61] Tang YL(1998)Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients Proc Natl Acad Sci USA 95 707-864

[62] Liang XH(2016)Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature Cytokine Growth Factor Rev 31 744-e174

[63] Allen CT(2016)Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Cancer Res 76 859-E93

[64] Clavijo PE(2014)Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors Acta Otolaryngol 134 e167-873

[65] Van Waes C(2012)Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice Med Oncol 29 292-622

[66] Chen Z(2010)The untold story of IFN-gamma in cancer biology Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 109 E85-343

[67] Reichert TE(2014)Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer Acta Otolaryngol 134 863-472

[68] Strauss L(2009)Regulatory T-cell infiltration in tongue squamous cell carcinoma Oral Oncol 45 617-2643

[69] Wagner EM(2009)The correlation between tumor-infiltrating Foxp3 BMC Cancer 9 335-1678

[70] Gooding W(2013) regulatory T cells and cyclooxygenase-2 expression and their association with recurrence in resected head and neck cancers Int J Cancer 132 465-597